RCUS
TEM
Another AI-healthcare handshake
Tempus and Recursion are back in the lab together. The two companies extended their existing data license agreement and also signed a fresh license agreement tied to Recursion’s RNA foundation model.
Why this matters
This is the kind of partnership that sounds nerdy until you remember that in biotech, data is basically jet fuel. Tempus keeps monetizing its health-data assets, while Recursion gets more raw material for its AI-driven discovery engine.
For Tempus, deals like this help reinforce the story that its data platform isn’t just a fancy database — it’s an asset other companies will pay to access. For Recursion, it’s another reminder that the company is trying to train models with real-world biological data instead of just vibes and slide decks.
The investor angle
The market usually likes these partnerships for the optionality more than the immediate dollars. If Tempus can keep stacking collaborations, it strengthens the bull case that its data moat is widening. If Recursion keeps stitching together useful licenses, it shows the company is still aggressively feeding its AI drug-discovery machine.
Big picture: this isn’t a moonshot headline, but it is another brick in the wall for both companies’ long-term AI-biotech narratives.